Biohaven Pharmaceuticals, Inc: Lead program is oral CGRP antagonist (targeting migraine); submitted NDAs for Zydis ODT (orally dissolving tablet) and tablet formulations of rimegepant in 2Q19. Upcoming milestones: 4Q19: (1) Ph 3 topline (preventive migraine) (2) Ph 2/3 topline (intranasal/acute treatment of migraine) (3) Ph 2/3 topline (gen. anxiety disorder) (4) Ph 2/3 interim (Alzheimer's); 1Q20: (5) Ph 2/3 topline (OCD)
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
215 Church Street
New Haven, CT 06510
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.